The Primary Care Research Network (PCRN) has recruited the 1000th control patient to the International Study of Incident Cancer (ISICA).
ISICA, sponsored by life-sciences company Sanofi Aventis, aims to assess the relative risk of breast cancer associated with diabetes treatment in patients with diabetes. Reaching the target of recruiting 1000 control patients in the UK is a significant step towards the success of this important study. The UK is one of three countries contributing to the study, along with France and Canada. In England the study was supported by both NCRN and PCRN with a target of recruiting 250 patients with breast cancer, and 1000 control patients, respectively.
Since January this year when ISICA opened, a total of 71 general practices in the UK contributed to the research, all of them PCRN sites. To date the study has recruited 1133 control patients, reaching the target of 1000 control patients through PCRN sites in early October in just 10 months. PCRN Northern and Yorkshire topped the leader board recruiting a phenomenal 381 patients through 23 practices.
Feedback from general practices that took part was very positive:
"A very well organised study with easy to use website to enter data and good support.”
Dr Tony Shaw, Moorlands Practice, Darlington
“…we have been astonished that so many of our patients have participated and pleased with the support and guidance from the ISICA team. We are glad that our first foray into supporting research has gone so well.”
Dr Sally Bastiman, Yarm Medical Practice, Stockton-on-Tees
For more infor contact the PCRN team: crncc.pcrn@nihr.ac.uk
